By testing a variety of gold nanoparticles, researchers are providing first evidence of their impact upon human B lymphocytes — the immune cells responsible for antibody production. The use of these nanoparticles is expected to improve the efficacy of pharmaceutical products while limiting potential adverse effects. These results will lead to the development of more targeted and better tolerated therapies, particularly in the field of oncology.